Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Duffaud

Showing results (51-60 of 132) with videos related to

Pageof 14
Sort By:
Cancers|March 7, 2020
Pan Aurora Kinase Inhibitor: A Promising Targeted-Therapy in Dedifferentiated Liposarcomas With Differential Efficiency Depending on Sarcoma Molecular ProfileJean Camille Mattei, Corinne Bouvier-Labit, Doriane Barets, et al.
Virchows Archiv : an International Journal of Pathology|December 16, 2015
Spatio-temporal genetic heterogeneity of CTNNB1 mutations in sporadic desmoid type fibromatosis lesionsJérôme Doyen, Valérie Duranton-Tanneur, Isabelle Hostein, et al.
Clinical Sarcoma Research|September 7, 2012
Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patientsFlorence Duffaud, Caroline Even, Isabelle Ray-Coquard, et al.
Journal of Palliative Medicine|February 17, 2012
Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative careSébastien Salas, Matthieu Frasca, Brigitte Planchet-Barraud, et al.
Targeted Oncology|June 5, 2021
Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter StudyAlmudena Callejo, Sara Faouzi, Olivier Bouché, et al.
Anti-Cancer Drugs|May 31, 2008
High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategyCharlotte Dupuis, Cedric Mercier, Chenguang Yang, et al.
Nature Communications|January 29, 2026
Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trialRobin L Jones, Roman Groisberg, Jean-Yves Blay, et al.
Scientific Reports|June 5, 2017
A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patientsFrançois Becher, Joseph Ciccolini, Diane-Charlotte Imbs, et al.
Therapeutic Drug Monitoring|October 14, 2006
A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapyJoseph Ciccolini, Cédric Mercier, Alexandre Evrard, et al.
The Oncologist|August 22, 2012
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)Patricia Pautier, Anne Floquet, Nicolas Penel, et al.
Pageof 14

Showing results (51-60 of 132) with videos related to

Sort By:
Pageof 14
Cancers|March 7, 2020
Pan Aurora Kinase Inhibitor: A Promising Targeted-Therapy in Dedifferentiated Liposarcomas With Differential Efficiency Depending on Sarcoma Molecular ProfileJean Camille Mattei, Corinne Bouvier-Labit, Doriane Barets, et al.
Virchows Archiv : an International Journal of Pathology|December 16, 2015
Spatio-temporal genetic heterogeneity of CTNNB1 mutations in sporadic desmoid type fibromatosis lesionsJérôme Doyen, Valérie Duranton-Tanneur, Isabelle Hostein, et al.
Clinical Sarcoma Research|September 7, 2012
Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patientsFlorence Duffaud, Caroline Even, Isabelle Ray-Coquard, et al.
Journal of Palliative Medicine|February 17, 2012
Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative careSébastien Salas, Matthieu Frasca, Brigitte Planchet-Barraud, et al.
Targeted Oncology|June 5, 2021
Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter StudyAlmudena Callejo, Sara Faouzi, Olivier Bouché, et al.
Anti-Cancer Drugs|May 31, 2008
High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategyCharlotte Dupuis, Cedric Mercier, Chenguang Yang, et al.
Nature Communications|January 29, 2026
Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trialRobin L Jones, Roman Groisberg, Jean-Yves Blay, et al.
Scientific Reports|June 5, 2017
A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patientsFrançois Becher, Joseph Ciccolini, Diane-Charlotte Imbs, et al.
Therapeutic Drug Monitoring|October 14, 2006
A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapyJoseph Ciccolini, Cédric Mercier, Alexandre Evrard, et al.
The Oncologist|August 22, 2012
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)Patricia Pautier, Anne Floquet, Nicolas Penel, et al.
Pageof 14